> **来源：[研报客](https://pc.yanbaoke.cn)** ```markdown # Angelalign (6699 HK) 1H26 Earnings Summary and Analysis ## Core Content Angelalign reported a strong 1H26 earnings performance, surpassing expectations. The company achieved its first semi-annual profit from overseas operations, which is a significant milestone indicating successful global expansion. This performance was driven by increased case volumes and improved profitability, with revenue and net profit both showing substantial year-over-year (YoY) growth. ### Key Financial Highlights - **Revenue**: Increased by 43% YoY to US\$231 million, reaching 51% of the prior full-year forecast. - **Net Profit**: Rose by 80% YoY to US\$25.5 million. - **Case Volumes**: - Mainland China: 37% YoY growth to 148,608 cases. - Overseas: 43% YoY growth to 168,001 cases. - **Case Volume Guidance**: Raised to 350,000 cases for each market in 2026. ### Domestic Performance - **Revenue**: Grew 25% YoY to US\$113 million. - **Gross Margin**: Expanded 2.6 percentage points YoY to 65.8%. - **SG&A Ratio**: Decreased by 3.1 percentage points YoY. - **Operating Margin**: Improved by 5.0 percentage points YoY to 24.2%. ### Overseas Performance - **Revenue**: Increased 65% YoY to US\$118 million, representing 51% of total revenue. - **Operating Profit**: Achieved profitability for the first time in 1H26 with US\$0.6 million. - **Adjusted Operating Profit**: Reached US\$9 million, driven by operating leverage and improved customer acquisition efficiency. - **Demand**: Remained strong despite a price increase, indicating improved doctor recognition of Angelalign's clinical outcomes and service capabilities. ## Main Points - **Strong Earnings Beat**: Angelalign's 1H26 results exceeded expectations, primarily due to overseas profitability. - **Global Expansion Success**: The overseas business became profitable ahead of expectations, which is a key indicator of the company's global growth strategy success. - **Market Penetration**: Continued growth in both domestic and overseas markets, with particular emphasis on lower-tier cities and early orthodontics in China. - **Margin Improvements**: Both domestic and overseas businesses saw improvements in gross and operating margins, driven by cost efficiencies and operational scaling. - **Investor Confidence**: The company raised its 2026E revenue and earnings forecasts by 7.5% and 1.0%, respectively. - **Valuation**: Based on SOTP, the target price was raised to HK\$114.21, reflecting confidence in future performance. ## Key Information - **Target Price**: HK\$114.21 (Previous: HK\$84.05). - **Upside Potential**: 18.8%. - **Current Price**: HK\$96.10. - **Valuation Metrics**: - Domestic business: 23x 2026E P/E and 5x 2026E P/S. - Overseas business: 5x 2026E P/S, in line with relevant peers. - **Stock Performance**: - 1-month: +20.3%. - 3-month: +35.5%. - 6-month: +35.3%. ## Peer Comparison (2026E) | Company | P/E (x) | P/S (x) | |---------------------|--------|--------| | Alcon | 20.4 | 3.3 | | Align Technology | 14.2 | 2.7 | | Straumann | 29.3 | 5.4 | | Stryker | 21.5 | 4.6 | | Boston Scientific | 14.6 | 3.3 | | Dexcom | 34.3 | 6.6 | | STAAR Surgical | 31.5 | 3.4 | | **Average** | 23.7 | 4.2 | ## Shareholding Structure - **CareCapital Orthotech Limited**: 51.0% - **Shore Lead Limited**: 12.4% ## Analyst Ratings - **CMBIGM Rating**: BUY - **Rationale**: Strong case growth momentum, improving profitability, and positive outlook for both domestic and overseas businesses. ## Risks - **Overseas Expansion**: May not meet expectations. - **Domestic VBP (Value-Based Pricing)**: Could affect margins and profitability. ## Financial Summary (2023A - 2028E) ### Income Statement | Metric | 2023A | 2024A | 2025A | 2026E | 2027E | 2028E | |----------------------|------|------|------|------|------|------| | Revenue (US$ mn) | 210 | 269 | 370 | 483 | 580 | 686 | | Gross Profit (US$ mn) | 131 | 168 | 233 | 304 | 364 | 434 | | Net Profit (US$ mn) | 8 | 12 | 28 | 30 | 49 | 64 | | Adjusted Net Profit (US$ mn) | 26 | 27 | 44 | 65 | 82 | 98 | ### Profitability Metrics | Metric | 2023A | 2024A | 2025A | 2026E | 2027E | 2028E | |----------------------|------|------|------|------|------|------| | Gross Margin (%) | 62.4 | 62.6 | 62.9 | 62.9 | 62.8 | 63.3 | | Operating Margin (%) | -1.9 | 2.3 | 8.3 | 8.9 | 10.1 | 10.9 | | Adj. Net Profit Margin (%) | 12.5 | 10.0 | 11.8 | 13.4 | 14.1 | 14.3 | ### Valuation Metrics | Metric | 2023A | 2024A | 2025A | 2026E | 2027E | 2028E | |----------------------|------|------|------|------|------|------| | P/E (x) | 273.7 | 170.2 | 72.9 | 70.5 | 42.9 | 33.0 | | P/B (x) | 4.3 | 4.3 | 4.1 | 4.7 | 4.3 | 3.9 | | Dividend Yield (%) | 1.2 | 0.4 | 5.7 | 4.8 | 1.4 | 1.8 | ## Conclusion Angelalign's 1H26 results reflect a significant turnaround, with both domestic and overseas operations contributing positively to the company's financial health. The overseas profitability is a major positive sign, and the improved margins suggest operational efficiency and strong demand. The company maintains a BUY rating, with an updated target price and revised earnings forecasts, indicating optimism about its future performance. ```